Trial Deeper - Printable Version +- Porn Leet (https://pornleet.com) +-- Forum: Porn Forum (https://pornleet.com/Forum-Porn-Forum) +--- Forum: Porn Movies (https://pornleet.com/Forum-Porn-Movies) +--- Thread: Trial Deeper (/Thread-Trial-Deeper)

Trial Deeper - pornagain - 07-21-2026 Trial Deeper Porn Sold : http://pornsold.com/trial-deeper/ . . . Deeper Discreet Deeper Buy Credits Deeper Premium Account Free Deeper Bbw Deeper Foot Fetish Deeper Daily Pass . We report results from a randomized phase 2 DEEPER trial (UMIN000018217, jRCTs061180022) to test the superiority of modified (m)-FOLFOXIRI plus weekly cetuximab over bevacizumab in patients with?The DEEPER trial (JACCRO CC-13) was designed to test the superiority of m-FOLFOXIRI +cetuximab over m-FOLFOXIRI+ bevacizumab, which is one of standard chemotherapy regimens, in patients with`For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment.^Conclusions: The final survival analysis of the DEEPER trial demonstrated favorable PFS and OS with m-FOLFOXIRI plus cet in pts with RAS/BRAF wild-type and left-sided mCRC. The m-FOLFOXIRI plus cet regimen may be a good option for initial therapy, offering longer survival times in pts with extra-hepatic metastases.~We performed a randomized phase II study, DEEPER trial (JACCRO CC-13) NCT02515734, to investigate the efficacy and safety of cetuximab (cet) vs. bevacizumab (bev) in combination with modified (m)-FOLFOXIRI (irinotecan 150 mg/m 2, oxaliplatin 85 mg/m 2, 5-FU 2400 mg/m 2) in previously untreated mCRC patients with RAS wild-type tumors (Tsuji A#A final analysis of the DEEPER trial presented at ASCO GI 2025 has demonstrated the benefits of m-FOLFOXIRI with cetuximab for patients with metastatic colorectal cancer.#A post-hoc sub-group analysis was performed according to metastasis status to evaluate the resection rate and survival time in RAS / BRAF wild-type (wt) and left-sided pts who were enrolled into the DEEPER trial (JACCRO CC-13) NCT02515734 comparing m-FOLFOXIRI plus cetuximab (Cet) and Bev as initial therapy for RAS wt mCRC pts.